Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: A multicenter pilot study

H. A. Burris, Charles Vogel, D. Castro, L. Mishra, M. Schwarz, S. Spencer, D. D. Oakes, A. Korey, E. K. Orenberg

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Intratumoral injections of cisplatin/epinephrine-injectable gel were administered weekly for 4 weeks in 45 patients with malignant tumors of various histologic types. Tumors were located on the skin and subcutaneous tissue primarily of the head, neck, and trunk, and on the tongue, oral pharynx, and esophagus. Patients were not candidates for surgery, radiation, or systemic chemotherapy. Each of the treated tumors (n = 82) was evaluated 2, 4, 8, and 12 weeks after the final injection. The initial dose of cisplatin was 1 mg/cm3 tumor volume, with escalation to 6 mg/cm3 allowed, depending on observed toxicities. The mean cumulative dose per patient for the four treatments ranged from 0.56 to 380 mg cisplatin. No dose-limiting cisplatin-related toxicities, such as nephrotoxicity, neurotoxicity, or ototoxicity, were observed. The overall objective tumor response rate was 50% (41 of 82), with 40% (33 of 82) complete responses and a median response duration of 160 days. Complete responses for adenocarcinoma and squamous cell carcinoma were 58% (21 of 36) and 38% (12 of 32), respectively. These results justified further clinical trials to evaluate the role of local chemotherapy with intratumoral cisplatin/epinephrine-injectable gel in the palliative treatment of patients with selected accessible solid tumors.

Original languageEnglish
Pages (from-to)496-503
Number of pages8
JournalOtolaryngology - Head and Neck Surgery
Volume118
Issue number4
DOIs
StatePublished - May 1 1998
Externally publishedYes

Fingerprint

Palliative Care
Cisplatin
Epinephrine
Multicenter Studies
Gels
Injections
Neoplasms
Drug Therapy
Subcutaneous Tissue
Pharynx
Tumor Burden
Tongue
Esophagus
Squamous Cell Carcinoma
Adenocarcinoma
Neck
Head
Clinical Trials
Radiation
Skin

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this

Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors : A multicenter pilot study. / Burris, H. A.; Vogel, Charles; Castro, D.; Mishra, L.; Schwarz, M.; Spencer, S.; Oakes, D. D.; Korey, A.; Orenberg, E. K.

In: Otolaryngology - Head and Neck Surgery, Vol. 118, No. 4, 01.05.1998, p. 496-503.

Research output: Contribution to journalArticle

Burris, H. A. ; Vogel, Charles ; Castro, D. ; Mishra, L. ; Schwarz, M. ; Spencer, S. ; Oakes, D. D. ; Korey, A. ; Orenberg, E. K. / Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors : A multicenter pilot study. In: Otolaryngology - Head and Neck Surgery. 1998 ; Vol. 118, No. 4. pp. 496-503.
@article{01c30140ed8a4bd5a65888d3e01d14cc,
title = "Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors: A multicenter pilot study",
abstract = "Intratumoral injections of cisplatin/epinephrine-injectable gel were administered weekly for 4 weeks in 45 patients with malignant tumors of various histologic types. Tumors were located on the skin and subcutaneous tissue primarily of the head, neck, and trunk, and on the tongue, oral pharynx, and esophagus. Patients were not candidates for surgery, radiation, or systemic chemotherapy. Each of the treated tumors (n = 82) was evaluated 2, 4, 8, and 12 weeks after the final injection. The initial dose of cisplatin was 1 mg/cm3 tumor volume, with escalation to 6 mg/cm3 allowed, depending on observed toxicities. The mean cumulative dose per patient for the four treatments ranged from 0.56 to 380 mg cisplatin. No dose-limiting cisplatin-related toxicities, such as nephrotoxicity, neurotoxicity, or ototoxicity, were observed. The overall objective tumor response rate was 50{\%} (41 of 82), with 40{\%} (33 of 82) complete responses and a median response duration of 160 days. Complete responses for adenocarcinoma and squamous cell carcinoma were 58{\%} (21 of 36) and 38{\%} (12 of 32), respectively. These results justified further clinical trials to evaluate the role of local chemotherapy with intratumoral cisplatin/epinephrine-injectable gel in the palliative treatment of patients with selected accessible solid tumors.",
author = "Burris, {H. A.} and Charles Vogel and D. Castro and L. Mishra and M. Schwarz and S. Spencer and Oakes, {D. D.} and A. Korey and Orenberg, {E. K.}",
year = "1998",
month = "5",
day = "1",
doi = "10.1016/S0194-5998(98)70208-6",
language = "English",
volume = "118",
pages = "496--503",
journal = "Otolaryngology - Head and Neck Surgery (United States)",
issn = "0194-5998",
publisher = "Mosby Inc.",
number = "4",

}

TY - JOUR

T1 - Intratumoral cisplatin/epinephrine-injectable gel as a palliative treatment for accessible solid tumors

T2 - A multicenter pilot study

AU - Burris, H. A.

AU - Vogel, Charles

AU - Castro, D.

AU - Mishra, L.

AU - Schwarz, M.

AU - Spencer, S.

AU - Oakes, D. D.

AU - Korey, A.

AU - Orenberg, E. K.

PY - 1998/5/1

Y1 - 1998/5/1

N2 - Intratumoral injections of cisplatin/epinephrine-injectable gel were administered weekly for 4 weeks in 45 patients with malignant tumors of various histologic types. Tumors were located on the skin and subcutaneous tissue primarily of the head, neck, and trunk, and on the tongue, oral pharynx, and esophagus. Patients were not candidates for surgery, radiation, or systemic chemotherapy. Each of the treated tumors (n = 82) was evaluated 2, 4, 8, and 12 weeks after the final injection. The initial dose of cisplatin was 1 mg/cm3 tumor volume, with escalation to 6 mg/cm3 allowed, depending on observed toxicities. The mean cumulative dose per patient for the four treatments ranged from 0.56 to 380 mg cisplatin. No dose-limiting cisplatin-related toxicities, such as nephrotoxicity, neurotoxicity, or ototoxicity, were observed. The overall objective tumor response rate was 50% (41 of 82), with 40% (33 of 82) complete responses and a median response duration of 160 days. Complete responses for adenocarcinoma and squamous cell carcinoma were 58% (21 of 36) and 38% (12 of 32), respectively. These results justified further clinical trials to evaluate the role of local chemotherapy with intratumoral cisplatin/epinephrine-injectable gel in the palliative treatment of patients with selected accessible solid tumors.

AB - Intratumoral injections of cisplatin/epinephrine-injectable gel were administered weekly for 4 weeks in 45 patients with malignant tumors of various histologic types. Tumors were located on the skin and subcutaneous tissue primarily of the head, neck, and trunk, and on the tongue, oral pharynx, and esophagus. Patients were not candidates for surgery, radiation, or systemic chemotherapy. Each of the treated tumors (n = 82) was evaluated 2, 4, 8, and 12 weeks after the final injection. The initial dose of cisplatin was 1 mg/cm3 tumor volume, with escalation to 6 mg/cm3 allowed, depending on observed toxicities. The mean cumulative dose per patient for the four treatments ranged from 0.56 to 380 mg cisplatin. No dose-limiting cisplatin-related toxicities, such as nephrotoxicity, neurotoxicity, or ototoxicity, were observed. The overall objective tumor response rate was 50% (41 of 82), with 40% (33 of 82) complete responses and a median response duration of 160 days. Complete responses for adenocarcinoma and squamous cell carcinoma were 58% (21 of 36) and 38% (12 of 32), respectively. These results justified further clinical trials to evaluate the role of local chemotherapy with intratumoral cisplatin/epinephrine-injectable gel in the palliative treatment of patients with selected accessible solid tumors.

UR - http://www.scopus.com/inward/record.url?scp=0031977851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031977851&partnerID=8YFLogxK

U2 - 10.1016/S0194-5998(98)70208-6

DO - 10.1016/S0194-5998(98)70208-6

M3 - Article

C2 - 9560102

AN - SCOPUS:0031977851

VL - 118

SP - 496

EP - 503

JO - Otolaryngology - Head and Neck Surgery (United States)

JF - Otolaryngology - Head and Neck Surgery (United States)

SN - 0194-5998

IS - 4

ER -